Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2017-02-01 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
Director's Dealing 2017
Director's Dealing
2017-02-01 English
Director's Dealing 2017
Director's Dealing
2017-02-01 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a Regulation FD Disclosure with an attached press release (Exhibit 99.1). The document length is 2633 characters, which is relatively short and primarily serves to announce the press release rather than provide detailed financial data or a full report. There is no indication of detailed financial statements or comprehensive report content such as an Annual Report (10-K) or Interim Report (IR). The document is not a certification or officer attestation, nor does it fit other specific categories like earnings release or management report. Given the nature of Form 8-K filings and the content described, this filing best fits the Regulatory Filings (RNS) category, which is a fallback for miscellaneous regulatory announcements and disclosures that do not fit other categories.
2017-02-01 English
PRIMARY DOCUMENT
Director's Dealing
2017-01-20 English
SC 13D
Major Shareholding Notification
2017-01-18 English
Director's Dealing 2017
Director's Dealing
2017-01-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.